Stock Events

Stock Events

Idorsia 

€3.78
0
+€0.06+1.56% Today

Statistics

Day High
3.83
Day Low
3.75
52W High
19.8
52W Low
1.32
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 19T.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is a competitor due to its focus on creating innovative drugs for serious diseases, similar to Idorsia's mission in the biopharmaceutical sector.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals competes in the biotech space, particularly in developing medications for conditions that overlap with Idorsia's target diseases.
Biogen
BIIB
Mkt Cap26.03B
Biogen competes with Idorsia in the neurology space, particularly in the development of treatments for neurological and neurodegenerative diseases.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a competitor because of its strong presence in the biopharmaceutical field, focusing on life-threatening diseases, a market that Idorsia also targets.
AMGEN
AMGN
Mkt Cap187.56B
Amgen competes with Idorsia in the biotech industry, focusing on innovative therapeutics in areas that may overlap with Idorsia's research and development.
Novartis
NVS
Mkt Cap297.32B
Novartis is a direct competitor in the pharmaceutical and biotech sectors, with a broad portfolio that includes treatments in areas where Idorsia is also active.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a global pharmaceutical company with a wide range of products that compete with Idorsia's developments, especially in the biopharmaceutical field.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie operates in similar therapeutic areas as Idorsia, making it a competitor in the biopharmaceutical industry, especially in areas like immunology and oncology.
Merck
MRK
Mkt Cap298.84B
Merck & Co. competes with Idorsia through its extensive range of healthcare products and medications, including in therapeutic areas targeted by Idorsia.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca is a competitor because of its focus on developing a wide range of pharmaceuticals in areas that overlap with Idorsia's interests, including cardiovascular, renal, and metabolism.

About

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Show more...
CEO
Mr. Jean-Paul Clozel M.D.
Employees
1100
Country
US
ISIN
CH0363463438

Listings

STU
DE
19T.STU
LSE
GB
0RQE.LSE
F
DE
19T.F
SW
CH
IDIA.SW

0 Comments

Share your thoughts

FAQ

What is Idorsia stock price today?▼
The current price of 19T.STU is €3.78 EUR — it has increased by +1.56% in the past 24 hours. Watch Idorsia stock price performance more closely on the chart.
What is Idorsia stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Idorsia stocks are traded under the ticker 19T.STU.
Is Idorsia stock price growing?▼
19T.STU stock has fallen by -0.73% compared to the previous week, the month change is a -14.43% fall, over the last year Idorsia has showed a -80.9% decrease.
How many employees does Idorsia have?▼
As of April 10, 2026, the company has 1,100 employees.
In which sector is Idorsia located?▼
Idorsia operates in the Health Care sector.
When did Idorsia complete a stock split?▼
Idorsia has not had any recent stock splits.
Where is Idorsia headquartered?▼
Idorsia is headquartered in Allschwil, US.